Literature DB >> 8418845

L-29, an endogenous lectin, binds to glycoconjugate ligands with positive cooperativity.

S M Massa1, D N Cooper, H Leffler, S H Barondes.   

Abstract

The soluble mammalian lactose-binding lectins L-14-I and L-29 are both secreted and bind to oligosaccharides on laminin, a large extracellular matrix glycoprotein containing polylactosamine chains. Because of the potential functional significance of these lectin-laminin interactions, we compared quantitative aspects of L-14-I and L-29 binding to immobilized laminin using recombinant lectins labeled with 125I. We report that the concentration-dependent binding of L-29 exhibits positive cooperativity whereas binding of L-14-I does not. Cooperative binding of L-29 can also occur on glycoconjugate substrates other than laminin and is not dependent on cystine bond formation or aggregation in solution. L-29 contains repetitive sequences within the N-terminal domain not present in L-14-I. This domain is not required for binding activity, but is required for positive cooperativity. Though the precise mechanism of interaction of L-29 with laminin remains to be determined, it apparently results in assembly of a lectin aggregate on the substrate surface, which could have important functional consequences.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418845     DOI: 10.1021/bi00052a033

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  74 in total

1.  Kinetic measurements of binding of galectin 3 to a laminin substratum.

Authors:  E A Barboni; S Bawumia; R C Hughes
Journal:  Glycoconj J       Date:  1999-07       Impact factor: 2.916

2.  Distance mapping of protein-binding sites using spin-labeled oligosaccharide ligands.

Authors:  N U Jain; A Venot; K Umemoto; H Leffler; J H Prestegard
Journal:  Protein Sci       Date:  2001-11       Impact factor: 6.725

Review 3.  Galectins in parasite infection and allergic inflammation.

Authors:  Anna R Young; Els N Meeusen
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 4.  Seeing strangers or announcing "danger": galectin-3 in two models of innate immunity.

Authors:  Sachiko Sato; Julie Nieminen
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

5.  Enhancement of bound-state residual dipolar couplings: conformational analysis of lactose bound to Galectin-3.

Authors:  Tiandi Zhuang; Hakon Leffler; James H Prestegard
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

6.  Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions.

Authors:  Malathy P V Shekhar; Pratima Nangia-Makker; Larry Tait; Fred Miller; Avraham Raz
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

7.  Galectin-3 Is a Target for Proteases Involved in the Virulence of Staphylococcus aureus.

Authors:  Jonas Elmwall; Jakub Kwiecinski; Manli Na; Abukar Ahmed Ali; Veronica Osla; Lindsey N Shaw; Wanzhong Wang; Karin Sävman; Elisabet Josefsson; Johan Bylund; Tao Jin; Amanda Welin; Anna Karlsson
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

8.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011

9.  Distinct effects on splicing of two monoclonal antibodies directed against the amino-terminal domain of galectin-3.

Authors:  Richard M Gray; Michael J Davis; Katherine M Ruby; Patricia G Voss; Ronald J Patterson; John L Wang
Journal:  Arch Biochem Biophys       Date:  2008-04-18       Impact factor: 4.013

10.  Dimeric Galectin-8 induces phosphatidylserine exposure in leukocytes through polylactosamine recognition by the C-terminal domain.

Authors:  Sean R Stowell; Connie M Arthur; Kristin A Slanina; John R Horton; David F Smith; Richard D Cummings
Journal:  J Biol Chem       Date:  2008-05-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.